References
- The U.S. Department of Health & Human Services. American Patients First 2018. [cited 2018 June 15]. Available from: https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf.
- Sarpatwari A, Avorn J, Kesselheim AS. An incomplete prescription: President Trump’s plan to address high drug prices. JAMA. 2018;319(23):2373-2374.
- Robinson JC, Howell S, Pearson SD. Value-based pricing and patient access for specialty drugs. JAMA. 2018;319(21):2169-2170.
- Papanicolas I, Woskie LR, Jha AK. Health care spending in the united states and other high-income countries. JAMA. 2018;319(10):1024–1039.
- Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 2015;24(3):294–301.
- World Health Organization. Fair Pricing Forum Amsterdam Netherlands. [cited 2018 June 15]. Available from: http://www.who.int/medicines/access/fair_pricing/FairPricingForum2017MeetingReport.pdf?ua=1.
- Hutubessy R, Chisholm D, Edejer -T-T-T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness Resour Allocat. 2003;1(1):8.
- Garner S, Rintoul A, Hill SR. Value-based pricing: L’Enfant terrible? Pharmacoeconomics. 2018;36(1):5–6.
- Kaltenboeck A, Bach PB. Value-based pricing for drugs: theme and variations. JAMA. 2018;319(21):2165–2166.
- Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935.
- Garrison LP Jr., Neumann PJ, Willke RJ, et al. A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR Special Task Force Report [7]. J Int Soc Pharmacoecon Outcomes Res. 2018;21(2):161–165.
- Chandra A, Garthwaite C. The economics of indication-based drug pricing. N Engl J Med. 2017;377(2):103–106.
- Gandjour A, Chernyak N. A new prize system for drug innovation. Health Policy. 2011;102(2):170–177.